| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Tannenbaum Renee P serves as a Director at ANIP and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 3 buys and 2 sells. Those positions are worth an estimated $2.2M at current prices.
Historically, Tannenbaum Renee P's trades have earned a middling insider score of 55/100 across 4 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of -5.8%.
The biggest single holding is ANIP (~$2.2M) as Director. The recent filings there lean toward selling, a net 3,800 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | ANIP Ani Pharmaceuticals Inc | Director | Sell | 1,800 | $81.15 | $146,070.00 | -6.7% | -7.5% | - | |
| Dec 12, 2024 | CRDF Cardiff Oncology, Inc. | Director | Buy | 10,000 | $3.42 | $34,224.00 | +100.0% | +26.9% | -26.9% | |
| May 16, 2024 | ANIP Ani Pharmaceuticals Inc | Director | Sell | 2,000 | $63.87 | $127,740.00 | -9.9% | -7.2% | -5.9% | |
| Sep 15, 2022 | CRDF Cardiff Oncology, Inc. | Director | Buy | 10,000 | $1.72 | $17,168.00 | +156.3% | -15.6% | +3.6% |